Related Experiment Video
Updated: Dec 13, 2025
Symptom Assessment of Patients with Allergic Rhinitis Using an Allergen Exposure Chamber
Published on: March 3, 2023
Research on allergic rhinitis improvement in asthmatic children after dust mite exposure reduction: a randomized,
Ming Chen1, YuFen Wu1, Shuhua Yuan1
1Department of Respiratory Medicine, Shanghai Children's Medical Center affiliated to Shanghai Jiaotong University of Medicine, Shanghai, 200127, China.
Insights
This study investigated Hestelia Mite Bait for reducing house dust mite (HDM) exposure in children with allergic rhinitis (AR) and asthma. The mite bait effectively improved AR symptoms and quality of life by reducing allergen triggers.
Area of Science:
- Pediatric Allergy and Immunology
- Environmental Health
- Respiratory Medicine
Background:
- Allergic rhinitis (AR) and asthma are prevalent respiratory inflammatory diseases in children, often co-occurring and exacerbated by house dust mites (HDMs).
- Reducing exposure to HDM allergens is crucial for managing AR and asthma attacks.
- Hestelia Mite Bait offers a novel approach to reduce HDM populations in the home environment.
Purpose of the Study:
- To evaluate the efficacy of Hestelia Mite Bait in improving allergic rhinitis symptoms in children with both AR and asthma.
- To assess the impact of reduced dust mite exposure on asthma control and quality of life.
Main Methods:
- A single-center, randomized, double-blind, cross-over trial involving 60 children (aged 3-12 years) diagnosed with AR and asthma, confirmed allergic to dust mites.
- Participants received either Hestelia Mite Bait or a placebo for 8 weeks, followed by a 4-week washout period and then the alternative intervention.
- Outcomes measured included visual analogue scale (VAS) for AR symptoms, Rhinitis Control Assessment Test (RCAT), Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ), dust mite levels, medication use, and asthma control (ACQ-5).
Main Results:
- The study aims to determine if Hestelia Mite Bait significantly reduces AR symptoms (VAS scores) compared to placebo.
- Secondary outcomes will assess improvements in rhinitis control, quality of life, asthma control, and reduction in acute asthma events.
Conclusions:
- This research will provide scientific evidence on the effectiveness of mite bait in mitigating allergic airway diseases in children.
- Findings may support the use of Hestelia Mite Bait as a practical intervention for reducing allergen exposure and managing pediatric AR and asthma.
Background:
Allergic rhinitis (AR) in children is a major respiratory inflammatory disease with a high incidence that is increasing yearly. In China, 54.93% of children with asthma have AR, which often requires synchronous treatment. House dust mites (HDMs) are common allergens that often cause attacks of AR and asthma. Reducing allergen exposure is one of the most important measures to control and treat AR and asthma attacks. Hestelia Mite Bait, containing 0.1% emamectin, is a new tool for trapping and killing dust mites, reducing the number of dust mites on mattresses and thereby potentially reducing stimulation by allergens and ultimately improving asthma and rhinitis symptoms. This single-centre, randomized, double-blind, cross-placebo trial will explore the improvement in AR in asthmatic children after dust mite exposure reduction.
Methods:
We will recruit 60 children (aged 3-12 years) who have been diagnosed with AR and asthma and are allergic to dust mites as confirmed by a serum allergen test. Participants will randomly receive the Hestelia Mite Bait intervention for 8 weeks and the placebo intervention for 8 weeks. There will be a 4-week washout period between the two interventions. The primary outcome is the visual analogue scale (VAS) score of AR symptoms; the secondary outcomes include the Rhinitis Control Assessment Test (RCAT) score, Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) score, changes in the dust mite level, drug usage for asthma and AR, Asthma Control Questionnaire-5 (ACQ-5) score, and frequencies of acute asthma attacks, emergency visits, and hospitalizations.
Discussion:
This study aims to scientifically and objectively evaluate the effects of mite bait on rhinitis and asthma improvement after dust mite exposure reduction and provides a convenient means for future prevention and treatment of allergic diseases involving the airways in children.
Trial Registration:
www.chictr.org.cn ChiCTR1900024688. Registered on July 21, 2019.
More Related Videos
06:34A Component-resolved Diagnostic Approach for a Study on Grass Pollen Allergens in Chinese Southerners with Allergic Rhinitis and/or Asthma
Published on: June 4, 2017
03:40Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
Published on: December 20, 2024
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:30Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:29Asthma-I: Introduction
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms: